Vogelxo

Not for use in women. Not interchangeable with other topical testosterone products. Other persons (esp. children) must avoid contact with application site. Secondary exposure to testosterone; promptly discontinue if signs of virilization in children and women occurs, until cause is identified. Monitor for worsening BPH. Evaluate for prostate cancer prior to and during therapy. Monitor hematocrit prior to initiation, 3–6 months after starting therapy, then annually; if elevation occurs, withhold until acceptable level. Preexisting cardiac, renal or hepatic disease (discontinue if edema occurs). Obesity. Chronic lung diseases. Testosterone and/or other anabolic androgenic steroid abuse. Periodically monitor serum testosterone, PSA, liver function, and lipid profile. Monitor serum calcium if risk of hypercalcemia. Monitor for venous thromboembolism; discontinue if suspected. Inform patients of possible increased risk of MI, stroke. Flammable. Elderly.